Free Trial
NASDAQ:ABSI

Absci Q4 2023 Earnings Report

Absci logo
$3.03 0.00 (0.00%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$3.02 -0.01 (-0.33%)
As of 05:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Absci EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Absci Revenue Results

Actual Revenue
$0.34 million
Expected Revenue
$1.75 million
Beat/Miss
Missed by -$1.41 million
YoY Revenue Growth
N/A

Absci Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 21, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Absci's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Absci Earnings Headlines

KeyBanc Reaffirms Their Buy Rating on AbSci (ABSI)
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
Absci price target raised to $9 from $5 at KeyBanc
See More Absci Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Absci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Absci and other key companies, straight to your email.

About Absci

Absci (NASDAQ:ABSI) operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

View Absci Profile

More Earnings Resources from MarketBeat